FXR agonists, by modulating bile acid metabolism, reducing inflammation, and attenuating fibrosis, may be particularly effective in patients with liver cirrhosis, where these pathological processes are central to the progression of portal hypertension. Here, NR1H4 is linked to portal hypertension.